3Phipps RIR Atherosclerosis: the emerging role of inflammmation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000: 97: 6930-2.
4Michelson AD. Barnard MR. Krueger LA. Frelinger AL 3rd.Furman MI. Evaluation of platelet function by flow cytometry. Methods 2000: 21: 259-70.
5Kaski JC. Chester MR. Chen L. Katritsis D. Rapid anglographic progression of coronary artery disease in patients with angina pectoris: the role of complex stenosis norphology .Circulation 1995: 92: 2058-65.
6Kai H. lkeda H. Yasukawa H. Kai M. Seki Y. Kuwahara F. et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary s vndronles. J Am Coil Cardiol 1998: 32: 368-72.
7Inokubo Y.Hanada H. Ishizaka H. Fukushi T. Kamada T.Okumura K.Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-7.
8Yan JC. Wu ZG. Li L. Zhong RQ. Kong XT. The clinical implications of increased expression of CD40L in patients with acute coronary syndromes, Chin Med J 2002: 115:491-3.
9Peng DQ. Zhao SP. Li YF. Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002: 319: 19-26.
10Phipps RP. Koumas L. Leung E. Reddy SY. Blieden T.Kaufman J. The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis. Curt Opin lnvestig Drugs 2001: 2: 773-7.
